PAIN
Volume 141, Issue 1 , Pages 14-18 , January 2009

Comparison of chronic analgesic drugs prevalence in Parkinson’s disease, other chronic diseases and the general population

  • Christine Brefel-Courbon

      Affiliations

    • Service de Pharmacologie Clinique, CHU Toulouse, France
    • INSERM, U825, Toulouse, France
    • Université Toulouse III Paul Sabatier, Toulouse, France
    • Corresponding Author InformationCorresponding author. Address: Department of Pharmacology, Faculty of Medicine, 37 allées jules Guesde, 31000 Toulouse, France. Tel.: +33 5 61 14 59 62; fax: +33 5 61 25 51 16.
    • ,
  • Sabrina Grolleau

      Affiliations

    • EA 3696, Toulouse, Université Toulouse III Paul Sabatier, France
    • ,
  • Claire Thalamas

      Affiliations

    • INSERM, Centre d’Investigation Clinique 9302, Toulouse, France
    • ,
  • Robert Bourrel

      Affiliations

    • CNAMTS – Service médical Midi-Pyrénées, France
    • ,
  • Valérie Allaria-Lapierre

      Affiliations

    • CNAMTS – Service médical Provence-Alpes-Côte d’Azur-Corse, France
    • ,
  • Robert Loï

      Affiliations

    • CNAMTS – Service médical Provence-Alpes-Côte d’Azur-Corse, France
    • ,
  • Joelle Micallef-Roll

      Affiliations

    • Fédération de pharmacologie et de toxicologie, CHU Timone, Marseille, France
    • ,
  • Maryse Lapeyre-Mestre

      Affiliations

    • Service de Pharmacologie Clinique, CHU Toulouse, France
    • EA 3696, Toulouse, Université Toulouse III Paul Sabatier, France

Received 6 November 2007 ,Revised 7 April 2008 ,Accepted 25 April 2008.

References 

  1. Blyth FM, March LM, Brnabic AJ, Jorm LR, Williamson M, Cousins MJ. Chronic pain in Australia: a prevalence study. Pain. 2001;89:127–134
  2. Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2007. Available at: doi:10.1016/j.pain.2007.08.013.
  3. Brandt-Christensen M, Kvist K, Nilsson FM, Andersen PK, Kessing LV. Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study. Mov Disord. 2006;21:1221–1225
  4. Brandt-Christensen M, Lopez AG, Nilsson FM, Andersen PK, Kessing LV. Depressive disorders and anti-parkinson drug treatment: a case register study. Acta Psychiatr Scand. 2007;115:466–472
  5. Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F, et al. Effect of levodopa on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord. 2005;20:1557–1563
  6. Catala E, Reig E, Artes M, Aliaga L, Lopez JS, Segu JL. Prevalence of pain in the Spanish population: telephone survey in 5000 homes. Eur J Pain. 2002;6:133–140
  7. Chan AW, MacFarlane IA, Bowsher DR, Wells JC, Bessex C, Griffiths K. Chronic pain in patients with diabetes mellitus: comparison with a non-diabetic population. Pain Clinic. 1990;3:147–159
  8. Chiò A, Magnani C, Schiffer D. Prevalence of Parkinson’s disease in Northwestern Italy: comparison of tracer methodology and clinical ascertainment of cases. Mov Disord. 1998;13:400–405
  9. Chopra A, Saluja M, Patil J, Tandale HS. Pain and disability, perceptions and beliefs of a rural Indian population: A WHO-ILAR COPCORD study. WHO-international league of associations for rheumatology. community oriented program for control of rheumatic diseases. J Rheumatol. 2002;29:614–621
  10. Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain. 1995;60:3–38
  11. Clark JA, Spiro A, Fincke G, Miller DR, Kazis LE. Symptom severity of osteoarthritis of the knee: a patient-based measure developed in the Veterans health study. J Gerontol A Biol Sci Med Sci. 1998;53:M351–M360
  12. Djaldetti R, Shifrin A, Rogowski Z, Sprecher E, Melamed E, Yarnitsky D. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology. 2004;62:2171–2175
  13. Duarte-Ramos F, Cabrita J. Using a pharmaco-epidemiological approach to estimate diabetes type 2 prevalence in Portugal. Pharmacoepidemiol Drug Safety. 2006;15:269–274
  14. Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA. The epidemiology of chronic pain in the community. Lancet. 1999;354:1248–1252
  15. Ford B. Pain in Parkinson’s disease. Clin Neurosci. 1998;5:63–72
  16. Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, Ory-Magne F, Slaoui T, Rascol O, et al. Levodopa raises objective pain threshold in Parkinson’s disease: a RIII reflex study. J Neurol Neurosurg Psychiatry. 2007;78:1140–1142
  17. Giuffrida R, Vingerhoets FJ, Bogousslavsky J, Ghika J. Pain in Parkinson’s disease. Rev Neurol. 2005;161:407–418
  18. Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DC. Pain in parkinson’s disease. Mov Disord. 1986;1:45–49
  19. Guidelines for ATC Classification and DDD Assignment. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology. Available at: http://www.whocc.no/atcddd/ [accessed December 2006].
  20. Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a WHO study in primary care. JAMA. 1998;280:147–151
  21. International Association for the Study of Pain. Classification of chronic pain. Pain 1986;3:S1–226.
  22. Koller WC. Sensory symptoms in Parkinson’s disease. Neurology. 1984;34:957–959
  23. Krein SL, Heisler M, Piette JD, Makki F, Kerr EA. The effect of chronic pain on diabetes patients’ self-management. Diabetes Care. 2005;28:65–70
  24. Lajugie D, Bertin N, Chantelou ML, Vallier N, Weill A, Fender P, et al. The prevalence of Parkinson’s disease and its cost to the French national health fund in metropolitan France in 2000. Rev Med Ass Maladie. 2005;36:113–122
  25. Latham J, Davis BD. The socioeconomic impact of chronic pain. Disabil Rehabil. 1994;16:39–44
  26. Lee MA, Walker RW, Hildreth TJ, Prentice WM. A survey of pain in idiopathic Parkinson’s disease. J Pain Symptom Manage. 2006;32:462–469
  27. Maggini M, Salmaso S, Alegiani SS, Caffari B, Raschetti R. Epidemiological use of drug prescriptions as markers of disease frequency: an Italian experience. J Clin Epidemiol. 1991;44:1299–1307
  28. Montagnier D, Barberger-Gateau P, Jacqmin-Gadda H, Dartigues JF, Rainfray M, Peres K, et al. Evolution of prevalence of depressive symptoms and antidepressant use between 1988 and 1999 in a large sample of older French people: results from the Personnes Agees Quid study. J Am Geriatr Soc. 2006;54:1839–1845
  29. Papoz L. Utilization of drug sales data for the epidemiology of chronic diseases: the example of diabetes. The EURODIAB Subarea C Study Group. Epidemiology. 1993;4:421–427
  30. Rochat P, Hallas J, Gaist D, Friis ML. Antiepileptic drug utilization: a Danish prescription database analysis. Acta Neurol Scand. 2001;104:6–11
  31. Sindrup HJ, Jensen TS. Efficacy of pharmacological treatment of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999;83:389–400
  32. Snider SR, Fahn S, Isgreen WP, Cote LJ. Primary sensory symptoms in parkinsonism. Neurology. 1976;26:423–429
  33. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson’s disease. Lancet Neurol. 2006;5:75–86
  34. Ubeda A, Cardo E, Selles N, Broseta R, Trillo JL, Fernandez-Llimos F. Antidepressant utilization in primary care in a Spanish region: Impact of generic and reference-based pricing policy (2000–2004). Soc Psychiatry Psychiatr Epidemiol. 2007;42:181–188
  35. Van de Vijver DA, Roos RA, Jansen PA, Porsius AJ, de Boer A. Estimation of incidence and prevalence of Parkinson’s disease in the elderly using pharmacy records. Pharmacoepidemiol Drug Safety. 2001;10:549–554
  36. Verhaak PF, Kerssens JJ, Dekker J, Sorbi MJ, Bensing JM. Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain. 1998;77:231–239

PII: S0304-3959(08)00234-0

doi: 10.1016/j.pain.2008.04.026

PAIN
Volume 141, Issue 1 , Pages 14-18 , January 2009

Article Tools